Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Clover Health Investments, Corp.    CLOV

CLOVER HEALTH INVESTMENTS, CORP.

(CLOV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Clover Health Investments : ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III Investors to Secure Counsel Before Important Deadline – CLOV, CLOVW, IPOC

02/23/2021 | 05:58pm EST

WHY: New York, N.Y., February 23, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III (NASDAQ: CLOV, CLOVW) (NYSE: IPOC) who: (1) purchased or otherwise acquired publicly traded Clover securities between October 6, 2020 and February 4, 2021, inclusive (the “Class Period”); and/or (2) purchased or otherwise acquired Clover securities pursuant or traceable to the registration statement and prospectus issued in connection with the December 2020 merger of Clover and Social Capital III of the important April 6, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Clover securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Clover class action, go to http://www.rosenlegal.com/cases-register-2030.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period and in the registration statement made false and/or misleading statements and/or failed to disclose that: (1) Clover’s Clover Assistant platform was under active investigation by the Department of Justice (“DOJ”) for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ’s investigation presented an existential risk to the Company, since it derives most of its revenues from Medicare; (3) Clover’s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology; (4) a significant portion of Clover’s sales were by way of an undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Clover class action, go to http://www.rosenlegal.com/cases-register-2030.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2021
All news about CLOVER HEALTH INVESTMENTS, CORP.
03/08ROBBINS GELLER RUDMAN & DOWD LLP  : Announces Lead Plaintiff Deadline in the Clo..
BU
03/06CLOV EQUITY ALERT : Kessler Topaz Meltzer & Check, LLP Announces that a Securiti..
PR
03/04CLOVER HEALTH INVESTMENTS  : Mass. General, and ACP Decisions Research Team Secu..
AQ
03/02CLOVER HEALTH INVESTMENTS  : ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Clover H..
PR
03/01CLOVER HEALTH INVESTMENTS, CORP. /DE : Results of Operations and Financial Condi..
AQ
03/01CLOVER HEALTH INVESTMENTS  : Posts Higher Q4 Revenue; Issues 2021 Revenue Outloo..
MT
03/01CLOVER HEALTH INVESTMENTS, CORP. /DE : Other Events, Financial Statements and Ex..
AQ
03/01CLOVER HEALTH INVESTMENTS  : Q4 2020 Shareholder Letter
PU
03/01CLOVER HEALTH INVESTMENTS  : Earnings Flash (CLOV) CLOVER HEALTH INVESTMENTS Rep..
MT
03/01CLOV INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Clover Health I..
BU
More news
Financials (USD)
Sales 2020 674 M - -
Net income 2020 -56,6 M - -
Net cash 2020 35,2 M - -
P/E ratio 2020 -8,34x
Yield 2020 -
Capitalization 2 973 M 2 973 M -
EV / Sales 2020 4,36x
EV / Sales 2021 2,77x
Nbr of Employees 327
Free-Float 25,3%
Chart CLOVER HEALTH INVESTMENTS, CORP.
Duration : Period :
Clover Health Investments, Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLOVER HEALTH INVESTMENTS, CORP.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 14,33 $
Last Close Price 7,35 $
Spread / Highest target 104%
Spread / Average Target 95,0%
Spread / Lowest Target 76,9%
EPS Revisions
Managers and Directors
NameTitle
Vivek Garipalli Chief Executive Officer & Director
Andrew Toy President, Director & Chief Technology Officer
Joseph Wagner Chief Financial Officer
Sophia Chang Chief Clinical Informatics Officer
Kumar Dharmarajan Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CLOVER HEALTH INVESTMENTS, CORP.-56.17%2 973
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED-0.44%42 265
VEEVA SYSTEMS INC.-6.41%38 592
OMNICELL, INC.3.62%5 353
PRO MEDICUS LIMITED32.49%3 500
SECTRA AB (PUBL)-13.36%2 864